PeptideHub
Home
PeptidesCalculatorProtocolsSchedule
HomePeptidesCalculatorProtocolsSchedule
Back to Encyclopedia
Weight ManagementPhase IIIIntermediate

CagriSema

Cagrilintide + Semaglutide Combination

Also known as: Cagrilintide/Semaglutide, NNC9204-1706 + Semaglutide

Overview

A fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) being developed by Novo Nordisk. By targeting two complementary appetite-regulating pathways, CagriSema aims to achieve unprecedented levels of weight loss in a single weekly injection.

Half-Life
~5-7 days (both components)
Typical Dose
2.4–2.4 mg
Frequency
Once weekly (semaglutide component; cagrilintide 2.4 mg)
Cycle Length
Ongoing / indefinite under medical supervision

Administration

Subcutaneous

Benefits

  • Projected weight loss exceeding 25% of body weight
  • Dual appetite suppression via amylin and GLP-1 pathways
  • Improved glycemic control
  • Single weekly injection for convenience
  • Potential superiority over semaglutide alone

Side Effects

  • Nausea and vomiting
  • Diarrhea and constipation
  • Abdominal discomfort
  • Injection site reactions
  • Potential hypoglycemia

Mechanism of Action

  • Cagrilintide activates amylin receptors in the brainstem to reduce appetite
  • Semaglutide activates GLP-1 receptors for additional appetite suppression
  • Dual mechanism slows gastric emptying more effectively than either agent alone
  • Combined effect on hypothalamic satiety centers for synergistic weight loss

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • MEN2 syndrome
  • Severe pancreatitis history
  • Severe gastrointestinal motility disorders

Storage & Reconstitution

Store at 2–8°C (36–46°F), protected from light. In-use storage conditions pending final formulation approval.

Common peptide amounts:1.5 mg3 mg

Research Summary

Phase 2 results showed CagriSema produced approximately 15.6% weight loss at 32 weeks, significantly exceeding the individual components. The Phase 3 REDEFINE trial program is evaluating the combination across multiple obesity and diabetes populations. Early data suggest potential for >25% weight loss with extended treatment. Novo Nordisk positions CagriSema as a next-generation obesity therapy.

Commonly Stacked With

Growth HormoneAOD-9604
Weight ManagementMOTS-c

This information is for educational purposes only. Always consult a qualified healthcare professional before using any peptide.